The PD-1 receptor, a major immune checkpoint inhibitor whose signaling is the target of multiple blockbuster anticancer drugs, differs functionally between rodents and humans in previously unknown ways. Researchers from the University of California, San Diego, and co-authors at the Chinese Academy of Sciences and the National Cancer Institute reported these findings in the Jan. 3, 2025, online issue of Science Immunology.
Transneural Therapeutics Inc. has described 5-HT2A receptor modulators reported to be useful for the treatment of depression, anxiety, substance abuse and dependence, and headache.
Chengdu Zeling Biomedical Technology Co. Ltd. has identified compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, inflammatory, autoimmune, cardiovascular, renal, gastrointestinal, respiratory and neurological disorders.
Researchers at Leiden University Medical Center and Universiteit Leiden have synthesized anthracyclins reported to be useful for the treatment of cancer.
Haisco Pharmaceutical Group Co. Ltd. has disclosed quinazolinone derivatives acting as poly(ADP-ribose) polymerase 14 (PARP-14; ARTD8) inhibitors reported to be useful for the treatment of cancer, atopic dermatitis and autoimmune disease.
The company is advancing a pipeline of therapeutics, including programs acquired from Denali Therapeutics Inc., focused on treating neurological, cardiometabolic and ophthalmic diseases.
Alesta Therapeutics BV has closed an oversubscribed €65 million (US$67 million) series A financing round designed to support development of its two small-molecule therapeutics.
RSS
